Gottlieb Alice B, Burge Russel, Malatestinic William N, Zhu Baojin, Zhao Yunyang, McCormack Julie, Kimel Miriam, Merola Joseph F
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
Dermatol Ther (Heidelb). 2023 Aug;13(8):1831-1846. doi: 10.1007/s13555-023-00969-1. Epub 2023 Jul 11.
Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient's perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks.
To describe patient-reported clinical and quality-of-life outcomes after initiating ixekizumab using data collected from the United States Taltz® Customer Support Program.
This was a 24-week prospective, observational study of commercially insured diagnosis-confirmed adults with PsO. Surveys were completed at weeks 0 (baseline), 2, 4, 8, 12, and 24 and included the Patient Report of Extent of Psoriasis Involvement questionnaire to assess the extent of body surface area (BSA) affected by PsO, itch and pain numeric rating scales, Patient Global Assessment of Disease Severity (PatGA), and Dermatology Life Quality Index (DLQI).
523 patients were included in the analysis. Proportions of patients with ≤ 2% BSA involvement were 34.5%, 40.1%, 50.9%, and 79.9% at weeks 0, 2, 4, and 24, respectively; 54.8% and 75.1% achieved National Psoriasis Foundation preferred (BSA ≤ 1%) and acceptable (BSA ≤ 3% or ≥ 75% improvement) responses at week 12, respectively. Improvements of ≥ 4 points in itch and pain were seen by week 2 in 21.1% and 28.0% of patients, respectively, which increased to 63.1% and 64.8% at week 24. Proportions of patients with PatGA scores of 0 (clear) or 1 were 13.4%, 24.1%, 34.0%, and 69.6% at weeks 0, 2, 4, and 24, respectively; and proportions with DLQI total scores of 0 or 1 [no or minimal impact] were 8.4%, 17.6%, 27.3%, and 53.8% at weeks 0, 2, 4, and 24, respectively.
Patient-reported improvements in BSA, itch, skin pain, dermatology-specific quality of life, and overall PsO severity were seen as early as 2 weeks after initiation and continued through week 24.
司库奇尤单抗是一种高度选择性的白细胞介素-17A单克隆抗体，于2016年被批准用于治疗中度至重度银屑病（PsO）。关于其在开始治疗后不久（2至4周）以及持续治疗24周时从患者角度评估的有效性的真实世界数据有限。
利用从美国Taltz®客户支持计划收集的数据，描述开始使用司库奇尤单抗后患者报告的临床和生活质量结果。
这是一项针对商业保险确诊的PsO成年患者的为期24周的前瞻性观察性研究。在第0周（基线）、第2周、第4周、第8周、第12周和第24周完成调查，包括银屑病累及范围患者报告问卷，以评估受PsO影响的体表面积（BSA）范围、瘙痒和疼痛数字评定量表、患者整体疾病严重程度评估（PatGA）以及皮肤病生活质量指数（DLQI）。
523名患者纳入分析。第0周、第2周、第4周和第24周时，BSA累及≤2%的患者比例分别为34.5%、40.1%、50.9%和79.9%；第12周时，分别有54.8%和75.1%的患者达到美国银屑病基金会推荐（BSA≤1%）和可接受（BSA≤3%或改善≥75%）反应。第2周时，分别有21.1%和28.0%的患者瘙痒和疼痛改善≥4分，到第24周时增至63.1%和64.8%。第0周、第2周、第4周和第24周时，PatGA评分为0（清除）或1的患者比例分别为13.4%、24.1%、34.0%和69.6%；第0周、第2周、第4周和第24周时，DLQI总分0或1[无或最小影响]的患者比例分别为8.4%、17.6%、27.3%和53.8%。
患者报告称，开始治疗后2周即可观察到BSA、瘙痒、皮肤疼痛、皮肤病特定生活质量和整体PsO严重程度的改善，并持续至第24周。
